Korean J Hematol.
1999 Feb;34(1):18-26.
Cytogenetical, Morphological, and Immunophenotypical Characteristics of Myeloid Malignancies with t (8;21)
- Affiliations
-
- 1Department of Clinical Pathology, Dong-A University College of Medicine, Pusan, Korea.
- 2Department of Internal Medicine, Dong-A University College of Medicine, Pusan, Korea.
- 3Department of Pediatrics, Dong-A University College of Medicine, Pusan, Korea.
- 4Department of Clinical Pathology4, College of Medicine, Pusan National University, Pusan, Korea.
Abstract
- BACKGROUND
Myeloid malignancies carrying t (8;21) (q22;q22) exhibit several characteristic features. This translocation is most often associated with acute myeloid leukemia with maturation (AML-M2), but rarely with myelodysplastic syndrome. We studied the correlation of cytogenetics, morphology, and immunophenotype in 21 myeloid malignancies carrying t (8;21).
METHODS
We analyzed 21 t (8;21) positive myeloid malignancies for morphology, immunophenotype and cytogenetics, retrospectively. We also performed reverse transcription polymerase chain reaction (RT-PCR) for AML1-ETO fusion transcripts using marrow slides stored at room temperature.
RESULTS
17 patients were diagnosed as French-American-British (FAB) type M2 and 4 cases as refractory anemia with excess blasts in transformation (RAEB-t). Three patients had marrow eosinophilia and 14 cases (67%) had Auer rods in leukemic blasts. Three patients (14%) developed granulocytic sarcomas. Four patients had variant t (8;21) translocation and 16 (76%) had secondary clonal abnormalities, most commonly loss of a sex chromosome (52%). 15 patients (83%) aberrantly expressed CD19. AML1-ETO fusion transcript of same size was observed in classic and variant t (8;21) translocation (11/14, 79%).
CONCLUSION
Our study showed that myeloid malignancies carrying t (8;21) have distinctive morphological, immunophenotypical, and molecular features. These results can be aid to understand the pathogenesis and stratify treatment of those malignancies in the future.